B+
Bull case
25%
Probability
Target price
$210.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
DVA
DaVitaBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$192.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+67.0
Score
AI commentary
Primary earnings evidence is strong, but the follow-up remains mixed: the Q2 operating release was positive on margin and cash flow, while the stock was at $180.67 by August 6 and a live quote snapshot showed a 4.25% daily decline. No reliable consensus surprise, analyst revision set, or social aggregate was available, and the direct public peer set is thin, so the thesis remains a monitoring-style Hold rather than a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-08-07
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-08-04eventQ2 results showed stronger margins and cash generation, but mature underlying volumeMedium impact
DaVita reported Q2 revenue of $3.554 billion, operating income of $579 million, diluted EPS of $4.02, operating cash flow of $490 million, and free cash flow of $256 million. Operating margin expanded to 16.3% from 14.1% in Q1, while normalized non-acquired treatment growth was only 0.3% year over year. No consensus beat or miss was provided. [#SEC-8K-2026-08-04]
2026-11-05catalystFollow-through on treatment volume, reimbursement, and cost trendsMedium impact
The next operating checkpoint is whether the 1.09% sequential increase in daily treatments and lower patient-care cost per treatment persist, while revenue per treatment and payer mix stabilize. The modest normalized volume growth and year-to-date cost increases leave execution sensitivity elevated. [#SEC-8K-2026-08-04]
2026-12-31catalystCash flow and repurchases provide shareholder-return supportMedium impact
DaVita generated $256 million of Q2 free cash flow and repurchased 2.2 million shares at an average $154.95; it also reported 0.2 million additional repurchases through August 4. The offset is a new $500 million Term Loan B-2 tranche, so capital returns must be weighed against leverage. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology